Yamaguchi K, Yanagi H, Shimizu K, Shichino Y, Nishiyama K, Mori H, Suzuki Y, Oida H, Nishibata K, Tanaka M, Yonezawa H, Fujita T
Fukui Institute for Safety Research, ONO Pharmaceutical Co., Ltd., Japan.
J Toxicol Sci. 1998 Jul;23 Suppl 3:435-55. doi: 10.2131/jts.23.supplementiii_435.
4-week repeated dose toxicity study with 4-week recovery test of sodium N-[2-[4-(2, 2-dimethylpropionyloxy) phenylsulfonylamino] benzoyl] aminoacetate tetrahydrate (ONO-5046.Na), a novel neutrophil elastase inhibitor, was conducted in beagle dogs. The dogs of both sexes were administered ONO-5046.Na intravenously at a daily dose of 0 (vehicle control), 7.5, 15 or 30 mg/kg. In the 15 mg/kg female group and the 30 mg/kg male and female groups, transient hypoactivity and ataxic gait were observed. It is considered that these symptoms were attributed to the pharmacological effect of ONO-5046.Na. Also, in the 30 mg/kg male and female groups, erythrocyte, hematocrit and hemoglobin were decreased. In the 30 mg/kg male group, lung weight was increased. However, histopathological examination revealed there were no changes in any organs including the lungs. There were no treatment-related changes in body weights, food consumption, ophthalmology, occult blood in feces, urinalysis, blood chemistry, electrocardiography, blood pressure, temperature, pulse rate, hepatic and renal function or necropsy. These results indicate that the NOAEL of ONO-5046.Na in dogs in 15 mg/kg/day for both sexes in this study.
用新型中性粒细胞弹性蛋白酶抑制剂N-[2-[4-(2,2-二甲基丙酰氧基)苯基磺酰氨基]苯甲酰]氨基乙酸钠四水合物(ONO-5046.Na)在比格犬中进行了为期4周的重复给药毒性研究及4周恢复期试验。对雌雄犬静脉注射ONO-5046.Na,日剂量分别为0(溶媒对照)、7.5、15或30mg/kg。在15mg/kg雌性组以及30mg/kg雄性和雌性组中,观察到短暂的活动减少和共济失调步态。认为这些症状归因于ONO-5046.Na的药理作用。此外,在30mg/kg雄性和雌性组中,红细胞、血细胞比容和血红蛋白降低。在30mg/kg雄性组中,肺重量增加。然而,组织病理学检查显示包括肺在内的任何器官均无变化。在体重、食物消耗、眼科检查、粪便潜血、尿液分析、血液生化、心电图、血压、体温、脉搏率、肝肾功能或尸检方面均未发现与治疗相关的变化。这些结果表明,在本研究中,ONO-5046.Na对犬的无观察到有害作用水平(NOAEL)为雌雄均15mg/kg/天。